Dresse M F, David M, Hume H, Blanchard H, Russo P, Van Doesberg N, Rivard G E
Hematology-Oncology, Hôpital Sainte-Justine, Montreal, Quebec, Canada.
Pediatr Hematol Oncol. 1991 Oct-Dec;8(4):329-34. doi: 10.3109/08880019109028806.
The Kasabach-Merritt syndrome is characterized by thrombocytopenia and localized coagulopathy associated with a hemangioma. Most techniques applied to eradicate the tumor or accelerate its involution (surgery, radiation therapy, embolization) are invasive and require transfusion of large amounts of blood products. In some cases, medical treatment is the only alternative. Efficacy of steroids and antifibronolytic agents has already been described, but even this approach is associated with the administration of blood products. We report two cases of infants with Kasabach-Merritt syndrome associated with cardiac and hepatic hemangiomas. At admission, both had signs of cardiac failure. They were successfully treated with prednisone and epsilon-aminocaproic acid (EACA). Blood products were not required once the diagnosis was made. These observations have important implications for the management of patients with Kasabach-Merritt syndrome because they show that even in severe cases blood transfusions can be avoided by the use of prednisone and EACA.
卡萨巴赫-梅里特综合征的特征是血小板减少和与血管瘤相关的局部凝血障碍。大多数用于根除肿瘤或加速其消退的技术(手术、放射治疗、栓塞)具有侵入性,需要输注大量血液制品。在某些情况下,药物治疗是唯一的选择。类固醇和抗纤溶药物的疗效已经有过描述,但即使是这种方法也与血液制品的使用有关。我们报告了两例与心脏和肝脏血管瘤相关的卡萨巴赫-梅里特综合征婴儿病例。入院时,两人都有心力衰竭的体征。他们接受泼尼松和ε-氨基己酸(EACA)治疗成功。一旦确诊,就不再需要血液制品。这些观察结果对卡萨巴赫-梅里特综合征患者的管理具有重要意义,因为它们表明即使在严重病例中,使用泼尼松和EACA也可以避免输血。